From Wikipedia, the free encyclopedia
Content deleted Content added
|
 |
|||
| Line 20: | Line 20: | ||
|
| routes_of_administration = [[Oral administration|By mouth]] |
| routes_of_administration = [[Oral administration|By mouth]] |
||
|
| class = |
| class = |
||
|
| ATC_prefix = |
| ATC_prefix = |
||
|
| ATC_suffix = |
| ATC_suffix = |
||
|
| ATC_supplemental = |
| ATC_supplemental = |
||
Latest revision as of 04:16, 24 December 2025
Chemical compound
Pharmaceutical compound
Monomethyl fumarate, sold under the brand name Bafiertam is a medication used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.[1] It is taken by mouth.[1]
The most common adverse reactions are flushing, abdominal pain, diarrhea, and nausea.[1]
It was approved for medical use in the United States in April 2020.[2][3]
Monomethyl fumarate alters the NFE2L2 (Nuclear factor erythroid 2-related factor 2) transcription factor.
NFE2L2 (or NRF2) is a basic leucine zipper (bZIP) protein that regulates the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation. Several drugs that stimulate the NFE2L2 pathway are being studied for treatment of diseases that are caused by oxidative stress.
Two precursors are also approved:
Society and culture
[edit]
Monomethyl fumarate is the international nonproprietary name (INN).[11]
